Psoriasis and rheumatoid arthritis are both autoimmune diseases. While they affect your body in different ways, they share some common elements. And some research suggests that having one of these ...

Surprisingly, nearly 10% of adults in the United States experience some form of skin condition affecting the area behind their ears, including ailments such as ear eczema and psoriasis in ears. This ...

The study assessed the use of the interleukin-23 inhibitor icotrokinra (Protagonist Therapeutics, Johnson & Johnson) in adult and adolescent patients with moderate-to-severe plaque psoriasis.

If you have psoriasis, a chronic condition that primarily affects the skin, you might not know that it can also affect your eyes. But the inflammation that causes lesions on your skin is systemic ...

Psoriasis can be alarming if you’re newly diagnosed. When you look at your patch (or patches) of thick, red skin, you probably want to know two things: How can I make this disappear? And how can ...

Living with psoriasis presents unique challenges, but with the right skincare routine, you can manage symptoms effectively and maintain healthy skin. This guide offers comprehensive insights into ...

The FDA slapped a clinical hold on a phase 1b plaque psoriasis trial after testicular toxicity was reported in dogs from a nonclinical test. Research into the use of BET inhibitors to treat cancer ...

"I'm quite old already, but I think it's within my lifetime. I think within my lifetime we may see curing of psoriasis," said Andrew Blauvelt, MD, of Blauvelt Consultants in Annapolis, Maryland ...

Psoriasis has many imitators, but one that comes very close is seborrheic dermatitis. That’s because both conditions can cause red, scaly, inflamed patches on your skin. To tell the two apart ...

The FDA has slapped a clinical hold on a Phase Ib trial of Vyne Therapeutics’ investigational BET blocker VYN202 for plaque psoriasis, the biotech revealed Friday. The regulatory freeze stems from ...

The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. Led by AbbVie’s Humira, biologic TNF ...

A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity ...